• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Ceftazidime/avibactam in severe infections]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [FilmArray® in Acute Respiratory Infections and Sepsis]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac defibrillator for primary prevention of sudden death]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation for severe aortic stenosis]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Aortic valve replacement with rapid deployment or sutureless valves]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 (dpp4) inhibitors in diabetes mellitus]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Single-use negative pressure wound therapy for acute and chronic wounds]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Tenofovir alafenamide in patients with HIV diagnosis]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Osimertinib in lung cancer]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Montelukast in patients with chronic allergic rhinitis and no asthma]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Mechanical devices for urinary incontinence]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet for refractory epilepsy]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy in pseudoarthrosis]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Bone marrow stem cell therapy for orthopedic conditions]
2018 Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Best practices to reduce medication administration errors (MAEs) in hospital centre (HC) and long term care facilities centre (LTCF)]
2018 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Diagnostic effectiveness and safety of elastography in liver fibrosis]
2018 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Analysis of the efficacy and safety of orthodontic-orthopedic maxillary expansion devices as an alternative to adenotonsillectomy and/or pharmacological treatment in the management of sleep apnea-hypopnea syndrome in pediatric patients]
2018 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphatic leukaemia, paediatric patients aged 1 year or older)]
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal strategies for the diagnosis of acute pulmonary embolism: a health technology assessment
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Composite resin versus amalgam for dental restorations: a health technology assessment
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Drugs for the management of rheumatoid arthritis: clinical evaluation
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Metastatic melanoma gap analysis
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy: a health technology assessment
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical evaluation of interventions for the management of insomnia: a review of reviews
2018 Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions for temporomandibular joint disorder: an overview of systematic reviews
2018 Canary Health Service [Safety, effectiveness, and cost-effectiveness of subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death]
2018 Canary Health Service [Cost-effectiveness of vaccination against herpes zoster]
2018 Canary Health Service [Nutritional treatment of adults with chronic kidney disease (CKD) and irreversible severe energy-protein malnutrition using ordinary food]
2018 Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2018 Canary Health Service [SEEKER System for the screening of lysosomal storage diseases]
2018 Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018 Andalusian Health Technology Assessment Area (AETSA) [Point of care test for differential diagnosis of virus versus bacteria in acute respiratory tract infection]
2018 Andalusian Health Technology Assessment Area (AETSA) [Cardiopoietic stem cells for the treatment of heart failure secondary to myocardial ischemia]
2018 Andalusian Health Technology Assessment Area (AETSA) [Health technology assessment network in the SSPA. Methodology and work procedures]
2018 Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guidelines on severe mental disorder]
2018 Agency for Care Effectiveness (ACE) 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications
2018 Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2018 Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2018 Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2018 Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2018 Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2018 Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2018 Health Information and Quality Authority (HIQA) Guidelines for the budget impact analysis of health technologies in Ireland
2018 Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and decision aid for cervical cancer screening]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (non-pretreated advanced follicular lymphoma) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Midostaurin (acute myeloid leukaemia) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Telotristat ethyl (carcinoid syndrome diarrhoea) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brodalumab (plaque psoriasis) - Addendum to Commission A17-42]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Addendum to Commission A17-38]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A17-40]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nonacog beta pegol (haemophilia B) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Search for guidelines for the update of the DMP "coronary heart disease"]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenegermin (moderate or severe neurotrophic keratitis) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Addendum to Commission A17-45]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the systematic treatment of parodontopathies]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Addendum to Commission A17-58]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "osteoporosis" - rapid report]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the application of fluoride varnish on milk teeth to prevent the development and progression of initial caries or new carious lesions - rapid report]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (cutaneous T-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic T cells (high-risk haematological malignancies) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - second Addendum to Commission H16-02C]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Addendum to Commission A17-60]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Targeted lung denervation using catheter ablation for chronic obstructive pulmonary disease - Addendum to Commission H16-01]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Non-invasive prenatal testing to determine the risk of autosomal trisomies 13, 18 and 21 in high-risk pregnancies]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sonidegib (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Motor-driven continuous passive motion (CPM) devices after interventions on the knee and shoulder joint]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glycerol phenylbutyrate (urea-cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]